Use of a combination of an inhibitor of phosphodiesterase type 5 (PDE5) specific to cyclic guanosine monophosphate (cGMP) and an angiotensin II receptor antagonist in preparing Medicine

摘要

1. Claim 1: a drug characterized by relieving, treating or preventing hypertension (including essential hypertension) is prepared by using a type 5 phosphate (PDE5) specific monosodium glutamate (GMPC) inhibitor and an antagonist of recipient 2, Pulmonary hypertension, secondary hypertension, isolated earthquake hypertension, diabetes related hypertension, allergy related hypertension, and newer hypnosis, congestive heart failure, angina, ictus,Diabetes and glucose tolerance disorders. Claim 4: used in any of the above requirements, characterized in that PDE5 inhibitors are selected from 5 - [2-etoxi-5 - (4-metr-1-piperazinilsulfonil) fenil] - 1-meth-3-n-propil-1, 6-dihydro-7h-pirazolo [4, 3-d] pirimidin-7-ona (sildenafoli);(6R, 12R) - 2, 3, 6, 7, 12, 12a-hexahydro-2-methyl-6 - (3, 4-methylenedioxyphenyl) - pyridine [2 ', 1': 6, 1] pyridine [3, 4-b] indol-1, 4-diona (tadalafil);2 - [2-etoxi-5 - (4-ethi-piperazin-1-il-1-sulfonil) - phenyl] - 5-meth-7-propil-3h-imidazo [5.1-f] [1.2.4] triazin-4-ona (vardenafoli);At its second session, the conference of the parties adopted the report of the conference of the parties of the Stockholm Convention on persistent organic pollutants on its second session. 6-dihydro-7h-pirazolo [4, 3-d] pirimidin-7-ona and acceptable agents. Claim 5: use in claim 4,The PDE5 inhibitors were selected from 5 - [2-etoxi-5 - (4-methyl-1-piperazinilsulfonil) fenil] - 1-met-3-n-propil-1, 6-dihydro-7h-pirazolo [4, 3-d] pirimidin-7-ona (sildenafoli) and salts from which the drug was accepted. Claim 6: use in Item 5, which is characterized by PDE5 inhibitors being sildenafoli's citric acid. Claim 7: used in any of the above requirements, characterized in that the antagonists of the angiopathy II receiver are selected from candesartano, prervantanto, irbestano, lostano, olmesartan, medoxomil olmesartano and saralasino,Rum, valsartano and salt acceptable for the drug. Claim 8: the usage in Item 7, which is characterized by: the combination of PDE5 inhibitor and angiopoietin II receptor antagonist is selected from the citric acid of sildenafol and candesatanan; the citric acid of sildenafol is selected from the citric acid of sildenafol and irbestano; the citric acid and losartano of sildenafol; Sildenafil citrate and olmesarto; sildenafil citrate and medoxomil olmesantano; sildenafil citrate and tantalum telluride; and sildenafil and valsartan.